Biotechnology company Rakuten Medical Inc announced on Monday that it has initiated a Phase 1 clinical trial of RM-0256 photoimmunotherapy in Japan.
RM-0256, an anti-PD-L1 antibody-light-activatable dye conjugate, is the third drug candidate developed by Rakuten Medical based on its Alluminox platform.
The first-in-human, open-label, non-controlled, dose-escalation trial will enrol 24 patients with solid tumours, including malignant skin tumours, who are refractory to or ineligible for standard treatment. It is funded by the Japan Agency for Medical Research and Development (AMED) to support the development of RM-0256 for advanced or recurrent malignant epithelial skin tumours, which are the initial target indication in this study.
The primary objectives of the study are to evaluate the safety and tolerability of RM-0256 photoimmunotherapy and to identify recommended drug and light doses for Phase 2 clinical development. Primary endpoints include dose-limiting toxicities and adverse events. Secondary endpoints include tumour response and pharmacokinetic parameters of RM-0256. Exploratory assessments will also evaluate biomarkers associated with RM-0256 photoimmunotherapy.
The Alluminox platform is Rakuten Medical's investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies.
Aelis Farma announces receipt of second positive safety recommendation for Down syndrome trial
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Eisai launches subcutaneous Leqembi Pen in Japan for early Alzheimer's disease
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme